T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

2014/10/13 by Daniel W Lee, James N Kochenderfer, James N. Kochenderfer +29 · 2 citations
Medicine · #Acute Lymphoblastic Leukemia research #CAR-T cell therapy research #Cutaneous lymphoproliferative disorders research

paper · doi:10.1016/s0140-6736(14)61403-3

openalex publication_date 2014/10/13 · crossref created 2014/10/13 · crossref issued 2015/02/01 · crossref published 2015/02/01 · crossref published-print 2015/02/01 · crossref deposited 2018/09/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29 · crossref indexed 2026/08/05

Citations

• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
• Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
• Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
• C-reactive protein: a critical update

Cited by

• Mechanisms of resistance to CAR T cell therapy
• Nirali N. Shah [wikipedia]